PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.\', \'Department of Pharmaceutical Sciences, Tohoku University Hospital.\', \'Division of Nephrology, Endocrinology, and Vascular Medicine, Division of Medical Sciences, and Department of Clinical Biology and Hormonal Regulation, Tohoku University, Graduate School of Medicine, Sendai, Japan.\', \'Department of Pharmacy, Yamagata University Hospital, and Department of Pharmaceutical Science, Faculty of Medicine, Yamagata University, Yamagata, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.18433/jpps31813
?:doi
?:hasPublicationType
?:journal
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
is ?:pmid of
?:pmid
?:pmid
  • 34048668
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all